PD173074

For research use only. Not for use in humans.

Pfizer辉瑞授权目录号：S1264

CAS No. 219580-11-7

PD173074 是一种有效的FGFR1抑制剂，在无细胞试验中IC50约为25 nM，也能抑制VEGFR2，IC50为100-200 nM，作用于FGFR1比作用于PDGFR和c-Src选择性高1000倍左右。PD173074 可在胃癌细胞中抑制增殖并促进凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 802.11	现货
5mg	RMB 575.36	现货
50mg	RMB 3867.14	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的PD173074发表文献102篇：

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Biomedicines, 2022, 10(3)601

PubMed: 35327403 ( click the link to review the publication )

Oncoimmunology, 2022, 11(1):2021619

PubMed: 35003900 ( click the link to review the publication )

Mil Med Res, 2022, 9(1):7

PubMed: 35093168 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(2):2002922

PubMed: 33511016 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3017

PubMed: 34021145 ( click the link to review the publication )

EMBO J, 2021, e107182

PubMed: 34086370 ( click the link to review the publication )

Mol Oncol, 2021, 10.1002/1878-0261.13145

PubMed: 34850536 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4720

PubMed: 33946884 ( click the link to review the publication )

Front Neurosci, 2021, 15:768262

PubMed: 34795557 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-021-01061-1

PubMed: 33829354 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):65

PubMed: 34267282 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )
Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )

Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7037

PubMed: 31065021 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )
Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )

Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Dev Biol, 2018, 433(2):416-432

PubMed: 28760345 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(45):39185-39196

PubMed: 29045789 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Sci Rep, 2017, 7:41986

PubMed: 28155881 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )

J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )

Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317712592

PubMed: 28718374 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )
Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1613-21

PubMed: 25535896 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )
Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

产品安全说明书

FGFR抑制剂选择性比较

生物活性

产品描述

靶点

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

体外研究

PD173074是FGFR1的ATP竞争性抑制剂， K_i约为40 nM。PD173074也是VEGFR2的有效抑制剂。相比FGFR1，PD173074弱抑制Src，INSR，EGFR，PDGFR，MEK和PKC的活性，IC 50值大1000倍以上。PD173074剂量依赖性地抑制FGFR1和VEGFR2的自身磷酸化，IC50 分别为1-5 nM和100-200 nM。^[1] PD173074以剂量依赖的方式抑制FGF-2促进的颗粒神经元存活，IC50是12 nM，活性是SU 5402的1,000倍以上。^[2] D173074特异性地抑制FGF-2-介导的少突胶质细胞（OL）谱系细胞的细胞增殖，分化和MAPK激活。^[3] 在多发性骨髓瘤（MM）细胞系中，PD173074对野生受体和FGFR3突变有活性。PD173074还以剂量依赖的方式有效地抑制FGFR3的自磷酸化，IC50约为5 nM。PD173074有力地降低了表达FGFR3的KMS11细胞和KMS18细胞的活力，IC50小于20 nM。aFGF刺激的MM细胞生长受PD173074抑制是和FGFR3的表达高度相关的。PD173074完全抑制由Y373C FGFR3介导而不是的Ras介导的NIH 3T3转化，这表明PD173074专门针对FGFR3基因介导的细胞转化和缺乏非特异性的细胞毒性作用。PD173074也诱导KMS11和KMS18细胞功能成熟。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1581	NIf5U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NELlWFVKSzVyPUCuNFEzOjVizszN	NGXneIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KG-1	NGrLOZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MULJR\|UxRTBwMEWxNlkh\|ryP	Ml72QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MFM-223	MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkDDTWM2OD1yLkKxOVc3KM7:TR?=	NEmyVlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EoL-1-cell	M3H0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEDpVWlKSzVyPUCuN\|I6QDRizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ECC10	NVTKWJhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NX7SbHV{UUN3ME2wMlM{QDl6IN88US=>	NGXoOVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
H-EMC-SS	NGXRVoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MoHGTWM2OD1yLkO0O\|E2KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
AN3-CA	M1TKcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfRdmU2UUN3ME2wMlQxOTN\|IN88US=>	NWqySmxXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HuO-3N1	M2jX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF7yNVdKSzVyPUCuOVQ3PTNizszN	NULJNpZrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RT-112	M3fZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmThTWM2OD1yLkW0O\|AyKM7:TR?=	MnHEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NEC8	M3fpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3iwUGlEPTB;MD61OlI5QSEQvF2=	NGPwXpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
D-263MG	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4SyN2lEPTB;MD63NVE2QSEQvF2=	NHXPW5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SW962	NV7TVYF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXfJR\|UxRTBwN{i5PFgh\|ryP	NYnsWY5TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
BV-173	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnXrTWM2OD1yLki0OlI{KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MFE-280	NV\SeZltT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmHVTWM2OD1yLki1PFczKM7:TR?=	Ml3NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HuH-7	NXuyWnh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVfJR2xqUUN3ME2xMlI1PDZ2IN88US=>	NGXwOmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RS4-11	NHLGSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWnJR\|UxRTFwM{O4PFYh\|ryP	M1\jV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DMS-114	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M17zeWlEPTB;MT6zOlc{PyEQvF2=	NV7NNXhCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MSTO-211H	NUntUGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXLJR\|UxRTFwNEezO\|gh\|ryP	M324ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DU-145	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml;3TWM2OD1zLkW4NlE4KM7:TR?=	M1vpVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A172	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MoPnTWM2OD1zLkewN\|U2KM7:TR?=	NXjMdIxxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SBC-1	NIHjNnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHPqdmJKSzVyPUKuNFk1KM7:TR?=	M37aTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
H9	NUW5[nNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHf0W4NKSzVyPUKuNVQ{ODZizszN	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-SNU-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlLZTWM2OD1{LkG4N\|k1KM7:TR?=	NYP2WJdpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H720	NFnIbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXLJR\|UxRTJwMkGyPFMh\|ryP	MnXiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC2218	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUjJR\|UxRTJwM{e5N\|kh\|ryP	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
G-401	NV;HcZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MXvJR\|UxRTJwNEexPFkh\|ryP	M3WzN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MPP-89	M2D1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3e5W2lEPTB;Mj60PFM3PCEQvF2=	MnrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
697	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2rZZWlEPTB;Mj62OVM{OSEQvF2=	M1\mS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KARPAS-45	NU\BcGM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlHYTWM2OD1{LkewO\|Q4KM7:TR?=	NV;LVnRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MG-63	NVLMWGptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mlf0TWM2OD1{Lkm0NlYzKM7:TR?=	MmfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	M3r5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NILGSW1KSzVyPUOuNFM1PzJizszN	M4X3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
G-402	M1i0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXHPUlZRUUN3ME2zMlEzPzJ5IN88US=>	M3fKV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NKM-1	NHfVOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3PVWmlEPTB;Mz6xN\|U3PCEQvF2=	NXT3R5FvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RH-18	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYDJR\|UxRTNwMUm1PVgh\|ryP	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1092	Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXXJR\|UxRTNwMUm2PUDPxE1?	NVOwblNkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RPMI-8226	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWjJR\|UxRTNwMkO0OFch\|ryP	NXLnV2ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GAMG	NGrhWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1PWSWlEPTB;Mz60OlU4PiEQvF2=	MmLkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HH	M37qVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmOyTWM2OD1\|LkS3Olc3KM7:TR?=	NHj1OYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RO82-W-1	NEG5d2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX;4PYNqUUN3ME2zMlQ6QDV3IN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CCRF-CEM	MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXvJR\|UxRTNwNUC0PFgh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NBsusSR	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYTJR\|UxRTNwNkO5Olkh\|ryP	MofhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CHL-1	NX32bXJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWPnVnFbUUN3ME2zMlY2Pzl7IN88US=>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LK-2	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NH[y[nBKSzVyPUOuOlcyOzNizszN	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
Hs-578-T	M1y4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1H2VGlEPTB;Mz62O\|g4OyEQvF2=	NUD3NGpkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CTB-1	NIfBSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NX7Ob5c4UUN3ME2zMlgxODVzIN88US=>	Mmi5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
ES5	M4TSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1rNVmlEPTB;Mz64N\|Y{PyEQvF2=	M3K2VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A204	Ml\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MmL3TWM2OD1\|LkmyNFc2KM7:TR?=	NIHKZZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SW780	NHnu[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmLBTWM2OD1\|LkmyNlQ2KM7:TR?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EW-3	M4LTV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmXpTWM2OD1\|Lkm4PVI{KM7:TR?=	M2fNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A704	M4rJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUfJR\|UxRTRwMki3NlMh\|ryP	NULMfmlJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LU-139	NXXiXndqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWnJR\|UxRTRwM{G1N\|Qh\|ryP	M1;wc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CAL-72	NFTrRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXjJR\|UxRTRwNEG3OFYh\|ryP	NUHZeHJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
D-336MG	M1flPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnTJTWM2OD12LkS2PFE4KM7:TR?=	M4DGd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LAMA-84	M2PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1\6UGlEPTB;ND61N\|MyKM7:TR?=	NUDCbWx5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GI-ME-N	NY\3Z2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoH4TWM2OD12LkW0PFEh\|ryP	NXzRPVhxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KM-H2	M{DsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{PsemlEPTB;ND61OVIzOiEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H209	NWnxXJBvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWq1b2dqUUN3ME20MlU5Ojh\|IN88US=>	M2HMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
IGROV-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MYrJR\|UxRTRwOEexOlgh\|ryP	NGm2fpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
L-363	NYTMT5hXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NFHiO\|RKSzVyPUSuPVY3PjVizszN	MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NYLxbINNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWq2XIpPUUN3ME21MlI1ODZizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HuO9	NYjxOnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn7KTWM2OD13LkO4PFQ{KM7:TR?=	M2PaRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NOS-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYqwd4ZMUUN3ME21MlczQTJ5IN88US=>	NY\vdYppRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1770	NFzuZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MWHJR\|UxRTVwOUWwN\|Ih\|ryP	NHTpUGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SF126	NVnlfGJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{PYdWlEPTB;Nj6yNVQxPiEQvF2=	NUeybY1wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ML-2	NF:0W41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGO5WZVKSzVyPU[uNlQ6PzdizszN	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CHP-134	M1jicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHLFVmpKSzVyPU[uNlUyQDJizszN	NXHVOod3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H1355	NIXNZ4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYXJR\|UxRTZwNEG3N\|Mh\|ryP	M2rXS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
TE-12	NEPnNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV\yS\|ZyUUN3ME22MlczPjdzIN88US=>	M3fYe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A4-Fuk	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXS4bHRrUUN3ME22Mlc{OTR{IN88US=>	MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MV-4-11	M1qySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVrJR\|UxRTZwN{[2NlYh\|ryP	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-UT-1	NFH4cnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NG\TTVJKSzVyPU[uPVE4QDRizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	NIDkTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkjmTWM2OD15LkC3O\|Y1KM7:TR?=	NGH0NYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ME-180	NFXnSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXzqPJkxUUN3ME23MlExPDB2IN88US=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-28	M2[2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1e3dGlEPTB;Nz6zO\|gyQSEQvF2=	NFjuTG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HAL-01	NFruWmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYrOUHN6UUN3ME23MlQ5OzRzIN88US=>	Mn7rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
ES8	NEKzPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MojkTWM2OD15Lk[5OlI3KM7:TR?=	NXrPPVdbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DB	NFHQV\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHG3W\|FKSzVyPUiuNVE2ODRizszN	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-NEP-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NITRe2ZKSzVyPUiuOFgyPDlizszN	NWHsTJp4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
COR-L88	NV3hd5doT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYjDbZFRUUN3ME24MlUxQThzIN88US=>	NWjJXHQ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	M16wZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NILX[G9KSzVyPUiuOVIzOTJizszN	NWLGbG4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H520	NGiwO4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mo\yTWM2OD16Lk[yNVU4KM7:TR?=	NULvZlBNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SW954	M{HON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mn:0TWM2OD16Lk[5O\|g3KM7:TR?=	M1u1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
TE-6	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4H6SGlEPTB;OD63OVE1OyEQvF2=	M4rQbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-283MED	NUPlV\|VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWnJR\|UxRTlwME[1N\|Qh\|ryP	NUO2R5FpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DBTRG-05MG	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV3JR\|UxRTlwMEm2NFch\|ryP	NHn3RpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H446	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVfJR\|UxRTlwMkm1NlYh\|ryP	MoLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HOS	M1Haemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmPCTWM2OD17LkO1NVM1KM7:TR?=	NETKVpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES4	NULSTmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M17U[mlEPTB;OT61NFU6PSEQvF2=	NV[0b\|RDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EW-13	NVKxOHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MYnJR\|UxRTlwOEmwOVUh\|ryP	NVvoRpVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
IST-MES1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFy3[FRKSzVyPUmuPVQ2OzRizszN	NXvuXGNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CAS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NV[3N3RnUUN3ME25Mlk4PjV7IN88US=>	M13RNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EM-2	NHi3e\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnzCTWM2OD1zMD6xN\|k{KM7:TR?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SW948	NV;wTY5kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEPHeIVKSzVyPUGwMlE5QDJizszN	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
OAW-42	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUXTS4NSUUN3ME2xNE42OjZ5IN88US=>	Ml;UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
BE-13	NFvkR2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIOxWXlKSzVyPUGwMlY2PzZizszN	NFPDfGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KU812	NVewbWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2\tfmlEPTB;MUCuO\|M6OSEQvF2=	M1PvdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-MEL-30	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2CwOmlEPTB;MUCuPFkxOSEQvF2=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A2780	NYHLRnZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3jKdWlEPTB;MUGuNFMxQCEQvF2=	M3TCe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
TGBC24TKB	M2fUd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{LQfmlEPTB;MUGuNFc{PyEQvF2=	NE\DWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
GOTO	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYHHT4Q5UUN3ME2xNU4zODh2IN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H526	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYnkWnFtUUN3ME2xNU4{QDN5IN88US=>	NGXvfJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
BHT-101	NGDzTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXHJR\|UxRTFzLkS0OVYh\|ryP	M1HCVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H1155	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnPyTWM2OD1zMT60PVQ4KM7:TR?=	NYHQfGtqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MCF7	M4TtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVPJR\|UxRTFzLk[xOlch\|ryP	MorGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MKN45	M1PEVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NF\0fJlKSzVyPUGxMlc6QTNizszN	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MOLT-16	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MVPJR\|UxRTFzLkm2PVIh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
YH-13	M1LNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3zpV2lEPTB;MUKuNFM1PiEQvF2=	NUTtWXlHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
P12-ICHIKAWA	NUTZPVlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\ENWx6UUN3ME2xNk4{QDR3IN88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GR-ST	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYHUVXFuUUN3ME2xNk42Ojl3IN88US=>	NVzjeoZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CAKI-1	M1rHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlPNTWM2OD1zMj63PVEh\|ryP	NWCyVGZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LXF-289	M{TwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2fFT2lEPTB;MUOuNFg{PSEQvF2=	MkX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MHH-PREB-1	NYrCSJpwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGDrboRKSzVyPUGzMlI4ODRizszN	M{[wRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EW-16	M3G2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIS5eHVKSzVyPUGzMlMyQDdizszN	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H82	NWXRXlJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M37PXmlEPTB;MUOuOFE6PSEQvF2=	MknQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MMAC-SF	NIjYR4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTF\|LkS1OFch\|ryP	NIjtbII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
COLO-684	NIXYfndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGrOSnBKSzVyPUGzMlU{OThizszN	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
QIMR-WIL	NXfKNXhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWXJR\|UxRTF\|LkixNFkh\|ryP	NFLJRm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NB69	Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zxfWlEPTB;MUOuPVg3QCEQvF2=	NIPYVpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H2291	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWPpNZpzUUN3ME2xOE41PDV\|IN88US=>	M2TYO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MKN7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mn:yTWM2OD1zND62Olc3KM7:TR?=	NVHLRW5jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HDLM-2	NVf6bIU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXydI1JUUN3ME2xOU4yOjh4IN88US=>	NXzPWG9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A253	Moi0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NW\JU3lLUUN3ME2xOU4{QDZ7IN88US=>	M136clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-LU-1	NXzC[oh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmLjTWM2OD1zNT65NFk1KM7:TR?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MEG-01	NUDi[XBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nhTWlEPTB;MUWuPVExPyEQvF2=	M2Dqd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-N-DZ	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MkXrTWM2OD1zNT65N\|c3KM7:TR?=	M3jYVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
H4	M{GzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{f6[mlEPTB;MU[uNFg5KM7:TR?=	NGT4NYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LU-65	M1nEbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX\JR\|UxRTF4LkOzPFQh\|ryP	M4rYOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-H1048	NHn5fWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MmPETWM2OD1zNj61NVY2KM7:TR?=	NGfLPGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LCLC-97TM1	M3LjXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlnaTWM2OD1zNj61PFg6KM7:TR?=	M2C2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CAL-120	NFXSbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTF4Lkm4O\|kh\|ryP	MnfaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
LU-134-A	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVzORpNWUUN3ME2xO{4{OzlzIN88US=>	NXjzbVNuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-MEL-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NI\pVHlKSzVyPUG3MlcyOjdizszN	NGT3boM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H69	NWryPIw1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWDJR\|UxRTF5LkmzNFch\|ryP	NGT6bo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MC116	NXLkTVRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmPQTWM2OD1zNz65O\|Uh\|ryP	MnH3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
UMC-11	M{CxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoDPTWM2OD1zOD6xO\|g5KM7:TR?=	NVLPRY1iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCC1395	NU\pUVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NF\6dYdKSzVyPUG4MlQ{ODFizszN	NXXyVWRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
no-10	NUOzdol1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVvTNZo5UUN3ME2xPE43Ozh6IN88US=>	M4DvSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NY	NEPBNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2Pj[WlEPTB;MUmuNFgxQSEQvF2=	MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
OS-RC-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NETTepVKSzVyPUG5MlEzPTJizszN	NUG2UZZtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
D-423MG	NX;5dW16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHqzbYNKSzVyPUG5MlM6PTJizszN	M3rCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LC-2-ad	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{PPTWlEPTB;MUmuO\|YyOiEQvF2=	M2XpUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DU-4475	NULqNHlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M363eGlEPTB;MUmuPFg2OiEQvF2=	MmDYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
YKG-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NUC2eZd4UUN3ME2xPU46PjJizszN	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HCC1569	MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRTJyLkK2NlQh\|ryP	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TYK-nu	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTJyLkK4OFch\|ryP	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DEL	MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWHxZXgzUUN3ME2yNE46QDB6IN88US=>	M3fCV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MHH-ES-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXvJXmc3UUN3ME2yNU4{PTl5IN88US=>	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KARPAS-299	NGPUcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUXuRnRyUUN3ME2yNU42OjlizszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CTV-1	Mly1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUnl[HFYUUN3ME2yNU43OTd{IN88US=>	NW\JWppSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H2452	MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkLBTWM2OD1{Mj62Olc4KM7:TR?=	MkfkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
D-566MG	Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{HQV2lEPTB;MkKuO\|YxOSEQvF2=	NH7qRXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EFO-27	NWW3XoN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NI[0cINKSzVyPUKzMlA3PTFizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H596	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX7JR\|UxRTJ\|Lki1Nlch\|ryP	MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KS-1	M1HGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYfJR\|UxRTJ2LkK3OVkh\|ryP	MoLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
8305C	NH7tcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUfrbZpZUUN3ME2yOE41ODR3IN88US=>	M1K0VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A427	M4jkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXHJR\|UxRTJ3LkCzNlMh\|ryP	NIO3XmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
COLO-800	MlrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYfJR\|UxRTJ3LkGwOlEh\|ryP	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SJRH30	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MX3JR\|UxRTJ3LkO5NFgh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MEL-HO	NWnMXW5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2rzXGlEPTB;MkWuOFMyQSEQvF2=	M1KzOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
FTC-133	NGjhXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnXUTWM2OD1{NT64NVg3KM7:TR?=	M2\leFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SF295	M2O0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUfJR\|UxRTJ4LkK5OkDPxE1?	M17uSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW1710	NWX0fIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NE\NVo9KSzVyPUK2MlQyOjNizszN	Moq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
EFM-19	M{O3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnHHTWM2OD1{Nj64NVQ2KM7:TR?=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NB10	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV3JR\|UxRTJ6LkKyPVch\|ryP	NIDoU\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TK10	NGXxNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml32TWM2OD1{OD6yN\|k6KM7:TR?=	NHnvO4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
D-502MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnK2TWM2OD1{OD60JO69VQ>?	NELKZ3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EW-18	NYD2bG1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUPjRo8yUUN3ME2yPE41Ozh4IN88US=>	NXXMdGRbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
VMRC-RCZ	NXTTUWFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV3JR\|UxRTJ6Lkm0NUDPxE1?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
Ca9-22	NHvj[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NELiUoJKSzVyPUK5MlQ2PTdizszN	NUmyVppHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KYSE-70	M1;hVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4\tTmlEPTB;MkmuOVc5PiEQvF2=	NU[1SXRuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A101D	NGnKOVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1G5dGlEPTB;MkmuOlQ4OiEQvF2=	M2DlNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
WM-115	NGm3fZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXzJR\|UxRTJ7Lke2NFch\|ryP	NIjZT2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HCC2157	NG\MNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYPJR\|UxRTJ7Lki4NFch\|ryP	NYX1T3hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
TE-9	NEL5THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4rtT2lEPTB;MkmuPFg3PSEQvF2=	MlPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
K-562	Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYrJR\|UxRTNyLkC5N\|Mh\|ryP	NIXURWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SN12C	NUmxS5FxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjofGpKSzVyPUOwMlE1OjZizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ESS-1	MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWrJR\|UxRTNyLkS3OVkh\|ryP	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
K5	NWnGfJpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MknMTWM2OD1\|MD63OlQh\|ryP	MoH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
J82	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MV7JR\|UxRTNzLkC4PVch\|ryP	MmjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HOP-92	NXy4bWJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4X6eWlEPTB;M{GuNVEyOSEQvF2=	MlG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H2228	NHHtZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml:wTWM2OD1\|MT6zNlk3KM7:TR?=	NF;aXIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
OCI-AML2	MnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYnJR\|UxRTNzLkO2NUDPxE1?	NWXSd\|FrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	MkfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTNzLkixN\|ch\|ryP	M3zh[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
A3-KAW	M2\3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUPJR\|UxRTNzLkmyOFMh\|ryP	MnHHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
LCLC-103H	Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYPRXpk3UUN3ME2zNk4xOTdzIN88US=>	M{XRdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KY821	NXjXWlFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoK4TWM2OD1\|Mj62PFg1KM7:TR?=	M1\yfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
JVM-2	M17jd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYTJR\|UxRTN{LkmwO\|kh\|ryP	NGXWZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Mo-T	NXHPeow{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVXqfpViUUN3ME2zN{4yODB3IN88US=>	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
IA-LM	MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3jmb2lEPTB;M{OuNlc2KM7:TR?=	M1:1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
C8166	MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUDGTohHUUN3ME2zN{4{OTl{IN88US=>	NH;nPVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TCCSUP	MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4fl[GlEPTB;M{OuOFMxPyEQvF2=	M37CfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
JEG-3	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M37WdWlEPTB;M{OuOFc3QCEQvF2=	Mn[yQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MS-1	M4XnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mnn5TWM2OD1\|Mz61OVUyKM7:TR?=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1304	NGfsbYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M1;xU2lEPTB;M{OuOVczPSEQvF2=	Mm\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
Ramos-2G6-4C10	M2K4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUHJR\|UxRTN2LkCzN\|Uh\|ryP	M4TF[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MDA-MB-453	NILqRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnLWTWM2OD1\|ND62N\|k2KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KYSE-520	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3qyeGlEPTB;M{SuO\|E5OSEQvF2=	NFewfYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SW900	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWDJR\|UxRTN2LkixNVUh\|ryP	MknNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HCC2998	NIXWSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVvJR\|UxRTN3LkG1Nlkh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A2058	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHfjd4tKSzVyPUO1MlYxPjFizszN	M2HxflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OVCAR-3	NIrvN\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MX3JR\|UxRTN4LkKwOFUh\|ryP	NUP6NHVYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MOLT-4	NVLz[3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2LZWGlEPTB;M{[uNlI6PCEQvF2=	MnX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CAPAN-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MWfJR\|UxRTN4LkS2PVkh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SCC-9	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2KweGlEPTB;M{euOFAzPyEQvF2=	NHfmcnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SF268	M4rmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NY\0fWRmUUN3ME2zPE4{PDN\|IN88US=>	M1TNclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HGC-27	M3[wSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mle0TWM2OD1\|OD6zO\|EyKM7:TR?=	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
DOHH-2	M2jKNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MonITWM2OD1\|OD63NVU5KM7:TR?=	NIriT2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KE-37	M2LOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NULiZlNVUUN3ME2zPE46QDJ6IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MOLT-13	M1vSemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2PE[2lEPTB;M{muNlUxOiEQvF2=	NF\L[289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES1	Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NF;IdIVKSzVyPUO5MlM5PSEQvF2=	MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-OV-3	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVmwVWNjUUN3ME2zPU46PjR\|IN88US=>	MoDaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SNU-449	M{jlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MljLTWM2OD12MD6wO\|Y1KM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KYSE-510	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{TLVGlEPTB;NECuNVI6PSEQvF2=	NGrBOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HL-60	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXX5SpVyUUN3ME20NE46Pzh\|IN88US=>	MnLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DJM-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXTtcIpJUUN3ME20NE46Pzl7IN88US=>	NVriemt7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
TGBC11TKB	NULoWnprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYrNd\|d5UUN3ME20NU4xQTJ4IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
U-2-OS	NF7OfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVPJR\|UxRTR{LkK2OFEh\|ryP	NXLyd4JRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H2030	M2D5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWjJR\|UxRTR{LkSzOlgh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-135	NXeze5N[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWTydIJjUUN3ME20Nk42PDR5IN88US=>	NHjEZ4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ZR-75-30	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVrJR\|UxRTR\|LkC0PVMh\|ryP	MnfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
GT3TKB	M3;2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1jCZmlEPTB;NEOuNlY4QSEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
RPMI-2650	NYjxc3loT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVPJR\|UxRTR\|Lke4NVYh\|ryP	MmewQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SAS	MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFTnO4lKSzVyPUSzMlk2OzRizszN	NIn6fY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MDA-MB-231	M3XFW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFXkc\|RKSzVyPUSzMlk3ODlizszN	M2\jVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
JVM-3	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUHpNmV4UUN3ME20OE4xPTN\|IN88US=>	NHvHUHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
COLO-320-HSR	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NULBVZNKUUN3ME20OE42PjN\|IN88US=>	NHn6OnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SNB75	M3vpPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3zJNmlEPTB;NESuOlExPSEQvF2=	MnW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H441	MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWLJR\|UxRTR2LkmzNlgh\|ryP	M{O0SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCT-116	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo\RTWM2OD12ND65PFY5KM7:TR?=	NG\RVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H226	NFn5TZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlrxTWM2OD12NT62N\|Y5KM7:TR?=	NUHMV3NYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CAL-33	MlLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnfhTWM2OD12NT65NlE4KM7:TR?=	MmTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H1437	MmS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{fte2lEPTB;NE[uN\|IyKM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HCC1187	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M17PT2lEPTB;NE[uOFI2PSEQvF2=	M3z5clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NUGC-3	NXKxTFhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGrpXIRKSzVyPUS2MlU4ODlizszN	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
T98G	MoLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVvNVYI{UUN3ME20O{42PDdizszN	M3SxS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OVCAR-8	MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1jpXGlEPTB;NEeuOlg{KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LB2241-RCC	NHi0UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4XFW2lEPTB;NEeuO\|I4KM7:TR?=	NHLtOo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H358	MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3jSUWlEPTB;NEiuNVE2OiEQvF2=	Mm\UQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
PANC-08-13	NUfK[2o{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{fReGlEPTB;NEiuNVg2OyEQvF2=	M3LsXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KP-N-YN	NF\xeIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Ml\GTWM2OD12OD6yNVAzKM7:TR?=	NHHz[409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1755	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NWe1TlV4UUN3ME20PE4zPzJ4IN88US=>	M4LUflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NCI-N87	NUXQc5ZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1nNOmlEPTB;NEiuNlk6OSEQvF2=	NWnOV41rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SUM52	MnTIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFey[os2KGSjeYO=	NUj1UXIySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGS2ZTOi2jbYDsbYZq\WRiU2XNOVIh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFEzOyEQvF2u	MmjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkGxOVYoRjJ6NUKxNVU3RC:jPh?=
RT112	M4nDbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NWLmTHBEPzJiaILz	NHnkT2pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLUNVEzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlAyPSEQvF2u	NETGfGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PVc1Oid-Mke1PVk4PDJ:L3G+
insect cells	MV;GeY5kfGmxbjDhd5NigQ>?		MmC3NVAhdWmwcx?=	MkXkTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDmeYxtKGynbnf0bEBpfW2jbjDGS2ZTOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhcW6\|ZXP0JINmdGy\|IHnuJJBz\XOnbnPlJI9nKFupYX3tZU0{OlCfQWTQJIFnfGW{IEGwJI1qdnNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yCkYYPl[EBz[WSrb3HjeIl3\SCoaXz0[ZIh[mmwZHnu[{Bie3OjeTygTWM2OCB;IECuNFIyPSEQvF2u	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUSzOlIoRjJ5OUG0N\|YzRC:jPh?=
SW780	MXXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NIjGWYk2KGSjeYO=	NX\XT4N4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDGS2ZTOy2jbYDsbYZq\WRiU2e3PFAh[2WubIOgZYZ1\XJiNTDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFg1OyEQvF2u	NHHnR2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEWyNVE2Pid-Mki1NlEyPTZ:L3G+
NIH/ 3T3	M4HV[2Z2dmO2aX;uJIF{e2G7		Mkj5OUBucW6\|	MY\Jcohq[mm2aX;uJI9nKF[HR1\SNkApfW6tbn;3ckBwemmpaX6pJI93\XKneIDy[ZN{\WRiaX6gcY92e2ViTlnIM{A{XDNiY3XscJMhcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgd5RqdXWuYYTpc44hf2m2aDDWSWdHKG[xcjC1JI1qdnNiYomgbY1ufW6xYnzveJRqdmdiYX7hcJl{cXNuIFnDOVAhRSByLkGg{txONg>?	M{[0fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{K2N\|M6Lz5{N{OyOlM{QTxxYU6=
NCI-H520	MlTYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MW[3JIRigXN?	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[JRmKxMYFueGyrZnnl[EBPS0lvSEWyNEBk\WyuczDh[pRmeiB5IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6yPFEh\|ryPLh?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDV{MUG1Okc,Ojh3MkGxOVY9N2F-
HUVEC	MlTxSpVv[3Srb36gZZN{[Xl?	NXu4N\|E3OTBibl2=	NXjHd3Y4OTRiaILz	NXjmcXBOUW6qaXLpeIlwdiCxZjDGS2ZTNW2nZHnheIVlKGGwZ3nv[4Vv\XOrczDpckBpfW2jbjDIWXZGSyClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDjZZBqdGyjcomgeJVj\SC\|cILveZRqdmdiYYSgNVAhdk1iYX\0[ZIhOTRiaILz	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR5NEO4O{c,OTZ2N{SzPFc9N2F-
HUVEC	NETJNFhHfW6ldHnvckBie3OjeR?=	Mnv6NVAxKG6P	NIjnRZIyPCCqcoO=	NGr4ZYRKdmirYnn0bY9vKG:oIF\HSnIudWWmaXH0[YQh[W6paX;n[Y5me2m\|IHnuJIh2dWGwIFjVWmVEKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPhdIltdGG{eTD0eYJmKHOycn;1eIlv\yCjdDCxNFAhdk1iYX\0[ZIhOTRiaILz	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjR5NEO4O{c,OTZ2N{SzPFc9N2F-
SJ-GBM2	NULuW2NIeUiWUzDhd5NigQ>?			M1HkSJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	M2HGXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	NHP1SodyUFSVIHHzd4F6			NVyzWpdmeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	M3jN[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	MnrXdWhVWyCjc4PhfS=>			MnzQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
BT-37	MmTHdWhVWyCjc4PhfS=>			MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MnfrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NIXmfotyUFSVIHHzd4F6			M13nfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NHT1ZoZyUFSVIHHzd4F6			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	M1;iR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NUPLS\|B4eUiWUzDhd5NigQ>?			M2DsZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NUS2R246eUiWUzDhd5NigQ>?			M{XNe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	NEfhe5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NWXIT5kyeUiWUzDhd5NigQ>?			NXrNUlV7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NUD1NlRReUiWUzDhd5NigQ>?			NET1WpJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
fibroblast cells	M{jyV5FJXFNiYYPzZZk>			MkDFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKGOxboTyc4whUGhid3ns[EB1gXCnIH\pZpJw[myjc4SgZ4VtdHN?	NHf3VG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	M{PSZZFJXFNiYYPzZZk>			MmPJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

体内研究

PD173074在1 mg/kg/day或2 mg/ka/day对小鼠给药可以剂量依赖性的方式有效阻止由FGF或VEGF诱导的血管生成，并没有明显的毒性。^[1] PD173074抑制FGFR3突变体转染的NIH 3T3细胞在裸鼠体内生长。在KMS11异种移植瘤模型中，PD173074抑制FGFR3导致肿瘤生长延缓，小鼠的存活率提高。^[4] 在H-510异种移植体中，PD173074阻断肿瘤生长和cisplatin相似，与对照假治疗的动物相比增加中位生存期。在H-69异种移植体中，PD173074在50％小鼠中的诱导作用长于6个月。这些效应是和切除肿瘤中增加的细胞凋亡相关的，而非破坏肿瘤血管。^[5]

激酶实验：^[1]	- 合并体外激酶抑制试验: 检测是使用全长FGFR-1激酶在100微升含25 mM HEPES缓冲液（pH7.4），150 mM氯化钠，10 mM MnCl_{2，0.2 mM的原钒酸钠，750 μg/mL谷氨酸和酪氨酸（4:1）的无规共聚物，各种浓度的PD173074，和60至75 ng酶中进行的。该反应通过加入[γ-³²P]ATP（含有0.4 μCi of [γ-³²P]ATP的5 μM ATP）起始，样品在25°C孵育10分钟。反应通过加入30％三氯乙酸和材料的沉淀到玻璃纤维滤垫上终止。过滤器用15％三氯乙酸洗涤三次，掺入[³²P]到谷氨酸酪氨酸聚合物衬底是通过计算保留在过滤器上的放射性来确定，通过WALLAC1250 betaplate阅读器读取。非特异性的活性被定义为温育不含酶的样品保留在过滤器上放射性。特异活性被确定为总活性（酶加缓冲液）减去非特异性活性。PD173074抑制FGFR-1的酶活性的IC50浓度用图解法测定。}
细胞实验：^[4]	- 合并 Cell lines: KMS11和 KMS18 Concentrations: 溶解在DMSO中至终浓度~100 nM Incubation Time: 48小时 Method: 在aFGF/肝素的存在下，细胞在PD173074浓度梯度中孵育48小时。活细胞的百分比由MTT法检测。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 诱导角膜新生血管的瑞士韦伯斯特小鼠 Dosages: 约2 mg/kg/day Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+corn oil	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download PD173074 SDF

分子量	523.67
化学式	C₂₈H₄₁N₇O₃
CAS号	219580-11-7
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
What is the half-life of PD173074(S1264) in vivo?
回答：
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

泛FGFR抑制剂

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
活性最高的FGFR抑制剂

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA批准的FGFR抑制剂

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
最新的FGFR抑制剂

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

研究领域

产品类型

定制您的化合物库

PD173074

客户使用Selleck生产的PD173074发表文献102篇：

产品安全说明书

FGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download PD173074 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

常见问题及建议解决方法

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

相关FGFR产品